Major Announcements - Jinling Mining has decided to suspend the public transfer of 100% equity and debt of JG Mining due to the lack of qualified buyers during the second public listing phase [4] - Huibo Yuntong's controlling shareholder and actual controller have voluntarily committed not to reduce their holdings of the company's stock during a specific period, coinciding with the planned acquisition of Baode Computer Systems [5] - Weigao Blood Purification is planning to purchase 100% equity of Weigao Purui through a share issuance, with trading expected to be suspended from October 20, 2025 [6] - Ganfeng Lithium intends to transfer part of its equity in Shenzhen Yichu to introduce a strategic investor for 664 million yuan, which will result in Shenzhen Yichu no longer being included in the consolidated financial statements [7] - Sanhua Intelligent Control has raised the upper limit for its share repurchase price from 35.75 yuan to 60.00 yuan and extended the implementation period by two months [8] - Jingwei Huikai plans to acquire 100% equity of ZTE Systems for 850 million yuan, entering the private network communication sector [9] Performance Reports - Cambrian reported a third-quarter net profit of 567 million yuan, with a revenue increase of 1332.52% year-on-year [10] - Hikvision's third-quarter net profit grew by 20.31%, with revenues of 239.4 billion yuan [12] - Kewell's third-quarter net profit increased by 110.36%, with revenues of 14.5 million yuan [13] - Siwei Technology expects a net profit increase of 140% to 169% for the first three quarters, driven by strong smartphone sector performance [14] - Shentong Technology's third-quarter net profit surged by 452.62%, with revenues of 4.86 billion yuan [15] - Huayou Cobalt's net profit for the first three quarters increased by 39.59%, benefiting from integrated operations and rising cobalt prices [16] - Shenghui Integration reported a third-quarter net profit growth of 93.89% [17] - Jinshi Yaya expects a net profit increase of 48.99% to 83.95% for the first three quarters due to successful commercialization of R&D projects [18] - Haida Group's net profit for the first three quarters grew by 14.31%, and the company plans to spin off its subsidiary for a Hong Kong listing [19] - Hanlan Environment anticipates a net profit increase of approximately 15.85% for the first three quarters [20] - Haitong Development's net profit for the first three quarters decreased by 38.47% due to market price declines and rising operational costs [21] - Explorer expects a net profit decline of 64.62% to 70.51% for the first three quarters due to poor sales in outdoor business [22] - Guoji General's net profit for the third quarter decreased by 46.73% due to a decline in project revenue recognition [23] Major Contracts - Xinjiang Jiaojian has been awarded a construction project worth 556 million yuan [24] - Robotech signed a contract worth approximately 761 million yuan, representing about 68.83% of its 2024 revenue [25] - Shengshi Technology signed a contract for the Hunchun Port project worth 102 million yuan [26] Shareholding Changes - Youfa Group's director plans to reduce his holdings by up to 3.54 million shares [27] - Shengbang shares' controlling shareholder plans to reduce holdings by up to 1.28% [28] - Hunan Silver's major shareholder plans to reduce holdings by up to 2% [29] Share Buybacks - Tonghua Dongbao plans to repurchase shares worth 20 million to 40 million yuan [30] - Shenzhen New Star intends to raise its share repurchase price limit from 18 yuan to 30 yuan [31] Financing Activities - Changsha Bank has received approval to issue capital instruments not exceeding 12 billion yuan [32]

Group 1 - The core viewpoint of the article highlights the significant year-on-year profit growth projections for several companies in the first three quarters [1] Group 2 - Company Sitaiwei expects a net profit increase of 140% to 169% year-on-year for the first three quarters [1] - Company Beifang expects a net profit increase of 56.90% to 70.74% year-on-year for the first three quarters [1] - Company Jinshiyao anticipates a net profit increase of 48.99% to 83.95% year-on-year for the first three quarters [1] - Company Hanlan Environment projects a net profit increase of 15.85% year-on-year for the first three quarters [1]

金石亚药表示，公司通过有效落实预算优化与费用管控等一系列措施，期间费用实现同比下降，保障了 公司整体业务的稳健发展；新材料与机械业务板块得益于前期部分研发项目的成功商业化，其收入与毛 利额均实现同比改善。 北京商报讯（记者 丁宁）10月17日晚间，金石亚药（300434）发布2025年前三季度业绩预告显示，公 司预计前三季度实现归属净利润约为8660.55万元至10692.63万元，同比预增48.99%—83.95%。 ...

Core Viewpoint - Jinshi Yayao (300434.SZ) expects a net profit attributable to shareholders of 86.61 million to 106.93 million yuan for the first three quarters, representing a year-on-year growth of 48.99% to 83.95% [1] Financial Performance - The net profit after deducting non-recurring gains and losses is estimated to be between 69.13 million and 89.45 million yuan, reflecting a year-on-year increase of 32.83% to 71.88% [1] - The impact of non-recurring gains and losses on net profit is expected to be approximately 17.48 million yuan [1] Operational Efficiency - The company has implemented effective budget optimization and cost control measures, resulting in a year-on-year decrease in period expenses, which has supported the overall stable development of the business [1] - The new materials and machinery business segments have benefited from the successful commercialization of certain R&D projects, leading to improvements in both revenue and gross profit compared to the previous year [1]

Core Viewpoint - The company expects a net profit of approximately 86.61 million to 106.93 million yuan for the first three quarters of 2025, representing a year-on-year growth of 48.99% to 83.95% [1] Financial Performance - The company has implemented effective budget optimization and cost control measures, resulting in a year-on-year decrease in period expenses, which supports the stable development of its overall business [1] - The new materials and machinery business segments have benefited from the successful commercialization of certain R&D projects, leading to improvements in both revenue and gross profit compared to the previous year [1] - The estimated impact of non-recurring gains and losses on net profit is approximately 17.48 million yuan [1]

Core Viewpoint - The company Jinshi Yao (300434.SZ) expects a significant increase in net profit for the first three quarters of 2025, indicating strong financial performance and effective cost management strategies [1] Financial Performance - The projected net profit attributable to shareholders is between 86.61 million and 107 million yuan, representing a year-on-year growth of 48.99% to 83.95% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 69.13 million and 89.45 million yuan, showing a year-on-year increase of 32.83% to 71.88% [1] Operational Efficiency - The company has implemented effective budget optimization and cost control measures, resulting in a year-on-year decrease in period expenses, which supports the stable development of its overall business [1] - The new materials and machinery business segments have benefited from the successful commercialization of previous R&D projects, leading to improvements in both revenue and gross profit [1]

Core Viewpoint - Jinshiyao expects a significant increase in net profit for the first three quarters, indicating strong business performance and effective cost management [1] Financial Performance - The net profit attributable to shareholders is projected to be between 86.61 million and 106.93 million yuan, representing a year-on-year increase of 48.99% to 83.95% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 69.13 million and 89.45 million yuan, with a year-on-year increase of 32.83% to 71.88% [1] - Non-recurring gains and losses are estimated to impact net profit by approximately 17.48 million yuan [1] Cost Management and Business Development - The company has implemented effective budget optimization and cost control measures, resulting in a year-on-year decrease in period expenses [1] - The new materials and machinery business segments have benefited from the successful commercialization of previous R&D projects, leading to improvements in both revenue and gross profit [1]

Core Viewpoint - The company expects a net profit of 86.61 million yuan for the first three quarters of 2025, representing a year-on-year increase of 48.99% [1] Financial Performance - The company has effectively implemented budget optimization and cost control measures, resulting in a year-on-year decrease in period expenses, which supports the stable development of its overall business [1] - The new materials and machinery business segments have benefited from the successful commercialization of certain R&D projects, leading to improvements in both revenue and gross profit compared to the previous year [1] - The estimated impact of non-recurring gains and losses on net profit for the reporting period is approximately 17.48 million yuan [1]

Sichuan Jinshi Asia Pharmaceutical Co., Ltd. 2025 Q1-Q3 Performance Forecast [I. Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company projects 2025 Q1-Q3 net profit to increase 48.99%-83.95%, reaching 86.61 million to 106.93 million yuan - The performance forecast period is from January 1, 2025, to September 30, 2025, with **net profit expected to be positive and increase year-on-year**[3](index=3&type=chunk) Key Financial Data for 2025 Q1-Q3 Performance Forecast | Indicator | Estimated Amount for Current Period (million yuan) | Year-on-Year Growth | Actual Amount for Same Period Last Year (million yuan) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 86.6055 — 106.9263 | 48.99% — 83.95% | 58.1291 | | Net Profit After Deducting Non-Recurring Gains/Losses | 69.1279 — 89.4488 | 32.83% — 71.88% | 52.0414 | [II. Communication with Accounting Firm](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The performance forecast data is a preliminary estimate by the finance department and is unaudited by an accounting firm - The data related to this performance forecast has **not been audited by an accounting firm**[5](index=5&type=chunk) [III. Explanation of Performance Changes](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Changes) Performance growth is attributed to budget optimization, lower period expenses, improved new materials and machinery business from R&D commercialization, and positive non-recurring gains - Through budget optimization and expense control, the company achieved a **year-on-year decrease in period expenses**, ensuring stable business development[6](index=6&type=chunk) - The new materials and machinery business segment saw **year-on-year improvements in revenue and gross profit** due to the successful commercialization of prior R&D projects[6](index=6&type=chunk) - During the reporting period, non-recurring gains and losses are expected to impact net profit by approximately **17.4776 million yuan**[6](index=6&type=chunk) [IV. Other Related Explanations](index=1&type=section&id=IV.%20Other%20Related%20Explanations) This performance forecast is a preliminary estimate, with detailed data in the 2025 Q3 report; investors are advised to note investment risks - This performance forecast is a **preliminary estimate** by the company's finance department, with specific data to be **detailed in the 2025 Q3 report**[7](index=7&type=chunk) - Investors are advised to make **cautious decisions** and be aware of **investment risks**[7](index=7&type=chunk) [V. Documents for Reference](index=1&type=section&id=V.%20Documents%20for%20Reference) The board of directors' explanatory statement on the 2025 Q1-Q3 performance forecast serves as a reference document - Documents for reference include the **board of directors' explanatory statement** on the 2025 Q1-Q3 performance forecast[8](index=8&type=chunk)

Group 1 - The stock price of Jinshi Asia Pharmaceutical increased by 2.00% on October 10, reaching 9.68 CNY per share, with a total market capitalization of 3.889 billion CNY [1] - Year-to-date, the stock price has risen by 18.32%, with a slight increase of 0.73% over the last five trading days, but a decline of 3.49% over the last 20 days and 3.39% over the last 60 days [1] - The company has seen a net inflow of 1.4607 million CNY from major funds, with significant buying and selling activity recorded [1] Group 2 - Jinshi Asia Pharmaceutical, established on July 15, 2004, and listed on April 24, 2015, is based in Chengdu, Sichuan, and Hangzhou, Zhejiang [2] - The company's main business includes the research, production, and sales of pharmaceuticals and health foods, with 82.76% of revenue coming from drug sales [2] - As of June 30, the number of shareholders increased by 14.00% to 22,800, while the average circulating shares per person decreased by 12.28% [2] Group 3 - Since its A-share listing, Jinshi Asia Pharmaceutical has distributed a total of 170 million CNY in dividends, with 71.9122 million CNY distributed over the past three years [3]